Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Detailed knowledge of protein changes in cerebrospinal fluid (CSF) across healthy and diseased individuals would provide a better understanding of the onset and progression of neurodegenerative disorders. In this study, we selected 20 brain-enriched proteins previously identified in CSF by antibody suspension bead arrays (SBA) to be potentially biomarkers for Alzheimer's disease (AD) and verified these using an orthogonal approach. We examined the same set of 94 CSF samples from patients affected by AD (including preclinical and prodromal), mild cognitive impairment (MCI), non-AD dementia and healthy individuals, which had previously been analyzed by SBA. Twenty-eight parallel reaction monitoring (PRM) assays were developed and 13 of them could be validated for protein quantification. Antibody profiles were verified by PRM. For seven proteins, the antibody profiles were highly correlated with the PRM results (r > 0.7) and GAP43, VCAM1 and PSAP were identified as potential markers of preclinical AD. In conclusion, we demonstrate the usefulness of targeted mass spectrometry as a tool for the orthogonal verification of antibody profiling data, suggesting that these complementary methods can be successfully applied for comprehensive exploration of CSF protein levels in neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationRaise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 2×
“Despite a general agreement that assays in preclinical research do not need to follow the same standards as assays used in clinical applications, it is increasingly evident that the success of biomarker discovery depends on validated analytical assays [21,23,24].”
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Self-citationPeterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288
Desiere, F. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj040 · Cited by 910 · cited 1×
“All 20 proteins, besides NBEA, were detected previously by MS analysis in CSF according to the PeptideAtlas database [26] with normalized peptide spectrum matches (PSMs) ranging from 0.”
Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C., Domon, B., Deutsch, E. W., Grant, R. P., Hoofnagle, A. N., Hüttenhain, R., Koomen, J. M., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036095 · Cited by 561 · cited 3×
“Despite a general agreement that assays in preclinical research do not need to follow the same standards as assays used in clinical applications, it is increasingly evident that the success of biomarker discovery depends on validated analytical assays [21,23,24].”
Obesity and Hypertriglyceridemia Produce Cognitive Impairment
Farr, S. A., Yamada, K. A., Butterfield, D. A., Abdul, H. M., Xu, L., Miller, N. E., Banks, W. A., & Morley, J. E. (2008) · Endocrinology · doi:10.1210/en.2007-1722 · Cited by 382 · cited 1×
“Interestingly while CCK levels physiologically increase in CSF after eating [47], an association between overeating and hippocampal impairment has been experimentally observed [43,44].”
Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
Cited by
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
“A cluster of CSF biomarkers, namely Tau, neurogranin, SNAP25 in this study, and also alpha-synuclein, Visininlike protein-1 (VILIP-1), GAP43 and Beta-secretase 1 (BACE-1) levels are increased in MCI and AD and correlate highly with one another [6,9,36,37].”
BackgroundZhou, M., Haque, R. U., Dammer, E. B., Duong, D. M., Ping, L., Johnson, E. C. B., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09285-8 · Cited by 92
Mendsaikhan, A., Tooyama, I., Bellier, J.-P., Serrano, G. E., Sue, L. I., Lue, L.-F., Beach, T. G., & Walker, D. G. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0862-8 · Cited by 57
Remnestål, J., Öijerstedt, L., Ullgren, A., Olofsson, J., Bergström, S., Kultima, K., Ingelsson, M., Kilander, L., Uhlén, M., Månberg, A., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00198-y · Cited by 56
“The NF-M antibodies have been extensively investigated and the developed sandwich assay shows that both antibodies (HPA023138 and HPA022845) bind NF-M, as previously verified by PRM-mass spectrometry in CSF [66].”
MethodSelf-citationSissala, N., Babačić, H., Leo, I. R., Cao, X., Forshed, J., Eriksson, L. E., Lehtiö, J., Fredolini, C., Åberg, M., & Pernemalm, M. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01753-2 · Cited by 25
Self-citation
Metadata
- Authors
- Andersson, A., Remnestål, J., Nellgård, B., Vunk, H., Kotol, D., Edfors, F., Uhlén, M., Schwenk, J. M., Ilag, L. L., Zetterberg, H., Blennow, K., Månberg, A., Nilsson, P., & Fredolini, C.
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 494
- Pages
- 79-93
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W2922333731
- Cited by
- 53
- References
- 13
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.cca.2019.03.243
- The paper
- Andersson, A., Remnestål, J., Nellgård, B., Vunk, H., Kotol, D., Edfors, F., Uhlén, M., Schwenk, J. M., Ilag, L. L., Zetterberg, H., Blennow, K., Månberg, A., Nilsson, P., & Fredolini, C. (2019). Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2019.03.243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.